CGTX vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 01, 2026

CGTX

48.5
AI Score
VS
CGTX Wins

MRNA

35.5
AI Score

Investment Advisor Scores

CGTX

49score
Recommendation
HOLD

MRNA

36score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CGTX MRNA Winner
Net Income -8.50M -2.82B CGTX
Operating Income -16.55M -3.07B CGTX
ROE -25.7% -32.6% CGTX
ROA -21.9% -22.9% CGTX
Total Assets 38.90M 12.34B MRNA
Cash 34.01M 2.60B MRNA
Current Ratio 7.03 3.29 CGTX
Free Cash Flow -8.62M -2.06B CGTX

Relative Price Performance (Last 90 Days)

CGTX 1M: +15.8% · 3M: -17.6% MRNA 1M: +156.0% · 3M: +204.7%

Current Technical Phase

CGTX

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 51

RSI (14): 51.2 · Price: $1.03

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (33.8% over 20 days), RSI 64

RSI (14): 64.1 · Price: $140.34

Fundamentals Snapshot

Metric CGTX MRNA
Market Cap
Forward P/E -4.7 -28.2
Trailing P/E
Revenue (TTM)
Revenue Growth 0.0% 0.0%
Gross Margin -0.7%
Operating Margin 0.0% -5.6%
EPS -0.17 -7.71
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, CGTX is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.